$8.800
+0.419 (+4.76%)Al cierre
Noticias de ECOR
Eventos de ECOR
electroCore Reports Q3 Revenue of $9.69M, Below Expectations
Reports Q3 revenue $9.69M, consensus $10.93M. "This quarter reflects the early stages of a more efficient commercial organization," said Joshua Lev, Co-Chief Executive Officer, President, and Chief Financial Officer of electroCore. "This quarter we delivered record net sales of $9.7 million, up approximately 12% from a year ago, while spending less to do it, leading to the lowest operating loss in our history. More importantly, we have evidence that the transformation is working. We are deliberately prioritizing profitable, sustainable long-term growth over short-term results, which underpins our confidence in accelerating revenue growth and an inflection point in positive Adjusted EBITDA in 2027."
Company Lowers 2026 Revenue Outlook to $39M-$42M
The company said, "The Company is revising its full-year 2026 revenue outlook to a range of $39 million to $42 million, from its prior guidance of greater than 30% revenue growth."
Company Projects 30% to 40% Revenue Growth for 2027
The company said, "The Company is also introducing preliminary 2027 revenue guidance of 30% to 40% revenue growth over full year 2026 revenue and expects to achieve its first quarter with positive Adjusted EBITDA by the end of 2027. This preliminary outlook reflects the Company's expectations regarding the continued expansion of representatives selling both gammaCore and Quell into VA accounts, improved accountability associated with smaller territories, replicating operating leverage nationally, and potential label expansion of Quell for CIPN, which remains subject to FDA clearance. The Company expects to refine this guidance range and provide additional commentary as appropriate in the future. A reconciliation of forward-looking Adjusted EBITDA to the most directly comparable GAAP measure is not provided because the timing and magnitude of certain reconciling items cannot be reasonably predicted without unreasonable effort."
electroCore Submits FDA 510(k) Application for Chemotherapy-Induced Neuropathy
electroCore announced that it has submitted a 510 premarket notification to the FDA seeking 510(k) clearance for its Quell wearable neuromodulation platform for the treatment of chronic chemotherapy-induced peripheral neuropathy.
electroCore Appoints Joshua Lev and Mike Fox as Co-CEOs
electroCore announced that it has appointed Joshua Lev and Mike Fox as co-CEO and members of the board of directors, effective September 8. Lev has been with the company since 2020 holding multiple roles, most recently acting as the interim president and CFO. Fox joined the company in April as the COO to accelerate our commercial efforts.
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.







